CYTOCOM

Cytocom, Inc. is a clinical-stage biopharmaceutical company developing novel small molecule immunotherapies targeting autoimmune, inflammatory, infectious diseases and cancers based on patented technology and our proprietary AIMS™ platform designed to restore immune homeostasis. Therapies developed under our AIMS™ platform programs are considered a new class of immunomodulatory drugs that adjust immune responses to halt or slow disease progression. Through AIMS™, we are expanding our understanding of the relationship between noroxymorphone and proenkephalin analogs to determine how multiple factors impact pharmacokinetic-pharmacodynamic relationships, potency, and selectivity. With the acquisition of Cleveland Biolabs, Cytocom has enhanced its AIMS™ platform with the inclusion of additional TLR agonists to an already robust suite of programs... After years of work with naltrexone and met-enkepahlin, and discovering their anti-angiogenic and anti-inflammatory properties, Cytocom..

Also known as: Cytocom, Inc.

Primary location: Fort Collins United States